Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Noxopharm Announce Pre-Clinical Evidence Confirms Veyonda Abscopal Effect (ASX:NOX)

Veyonda® is being developed as a transformative anti-cancer treatment (DARRT) in combination with radiotherapy to produce off-target responses known as an abscopal effect Pre-clinical...read more

Netlinkz, China Distribution Expansion (ASX:NET)

China Distribution Expansion Netlinkz Ltd is pleased to announces that a Strategic Cooperation Agreement has been signed between Sichuan Meixunda Communications Corporation, a wholly-owned subsid...read more

Noxopharm August 2019 Corporate Presentation (ASX:NOX)

Noxopharm Limited (ASX: NOX) (‘Noxopharm’ or the ‘Company’) today releases its August 2019 Corporate Presentation ahead of Australian and U.S. roadshows. The Presentation ...read more

NetLinkz announce product launch at AWS Summit, Beijing (ASX:NET)

NetLinkz Ltd (ASX: NET) announces the official launch of the first two products from the IoT Lab in Beijing at the AWS (Amazon Web Services) Summit For further information please download the attac...read more

NetLinkz Announce Grant Thornton Australia appointed as a strategic advisor (ASX:NET)

NetLinkz Ltd (ASX: NET) announces it has signed a Memorandum of Understanding to appoint Grant Thornton Australia as a strategic advisor for the Company for corporate advice, product sales and develop...read more

Noxopharm announce Appendix 4C - June 2019 Quarter (ASX:NOX)

Positive results from two prostate cancer trials Phase 2 trial design gaining momentum Investigational New Drug Application to be submitted to FDA in Q3 2019 Pipeline developi...read more

Noxopharm Announces AU$26 Million Funding Facility (ASX:NOX)

Key Highlights AU$4,000,000 initial funding Equity placement component of up to additional AU$22,000,000 in ordinary shares over 12 month Flexible funding package leadin...read more

Noxopharm Announces Board Changes Ahead of Corporate Growth (ASX:NOX)

Board Changes Ahead of Corporate Growth Key Highlights Experienced pharma executive, Dr Beata Niechoda, joins Noxopharm Board Mr John Moore becomes Executive Chairman of Noxopha...read more

Netlinkz Announce Joint Venture with iSoftStone Information Technology (ASX:NET)

Netlinkz Ltd (ASX: NET) announces it has signed a Memorandum of Understanding with iSoftStone Information Technology (Group) Co. Ltd (ISS) to establish a joint venture company in China to distribute a...read more

Netlinkz announces China revenue from China Telecom Wuxi Pilot (ASX:NET)

NetLinkz Ltd (ASX: NET) ('NetLinkz') is pleased to announce that today it has received cash proceeds of AUD$160,000 for the sale of VINs as a VPN replacement product from its pilot program wit...read more

U.S. Conference Hears of Positive Interim Data from LuPIN Trial (ASX:NOX)

KEY HIGHLIGHTS LuPIN study enrolling heavily pre-treated men with progressive late-stage prostate cancer (mCRPC) Clinical data shows combining Veyonda with radiopharmaceutical, 177Lu-PSM...read more

Noxopharm Corporate Presentation June 2019 (ASX:NOX)

SYDNEY, June 6, 2019: Noxopharm Ltd (ASX: NOX) (Noxopharm or ‘Company’) is pleased to provide the market with its updated corporate presentation for June 2019. For further inf...read more

Noxopharm’s DARRT-1 Study Fully Enrolled (ASX:NOX)

Final patient enrolled into study Topline data to be announced in Q4 2019 SYDNEY, 30 May 2019: Noxopharm (ASX: NOX) (‘Noxopharm’ or the ‘Company’) is pleased to...read more

Promising Data Leads to Expansion of Noxopharm’s LuPIN Trial (ASX:NOX)

LuPIN trial to recruit additional 24 patients Additional patients to be treated with Veyonda? 1200 mg The objective is to see whether the dose-response effect seen to date will lead...read more

Noxopharm’s LuPIN Trial Demonstrates High Rates of Response (ASX:NOX)

Data published today describes positive interim results from the LuPIN trial Veyonda? (NOX66) dose-finding study 69% combined PSA response rate is higher than that observed in studies of ...read more

Viewing: 1 - 15 of 200 Previous | Next